Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APT Alpha Pro Tech	$4.80 +2.1%	$4.66	$4.06 ▼ $6.44	$52.15M	0.32	28,375 shs	19,942 shs
INGN Inogen	$6.68 +2.1%	$6.63	$5.70 ▼ $13.33	$179.63M	1.66	243,282 shs	291,996 shs
PROF Profound Medical	$5.70 -1.0%	$5.68	$3.90 ▼ $11.42	$171.29M	0.49	65,011 shs	40,081 shs
TLSI TriSalus Life Sciences	$4.72 +0.2%	$5.24	$3.50 ▼ $6.04	$178.60M	0.5	52,092 shs	31,457 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APT Alpha Pro Tech	-0.84%	-3.49%	+1.95%	+8.42%	-20.14%
INGN Inogen	-0.15%	-12.80%	-0.91%	-4.11%	-32.92%
PROF Profound Medical	+1.05%	-2.37%	-15.04%	+20.50%	-40.62%
TLSI TriSalus Life Sciences	-0.63%	-5.99%	-14.52%	-17.94%	-12.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APT Alpha Pro Tech	1.1435 of 5 stars	0.0	4.0	0.0	0.6	0.8	1.9
INGN Inogen	4.2733 of 5 stars	3.3	4.0	3.9	1.5	1.7	1.3
PROF Profound Medical	2.9144 of 5 stars	3.5	2.0	0.0	3.3	2.5	0.6
TLSI TriSalus Life Sciences	3.0205 of 5 stars	3.6	2.0	0.0	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APT Alpha Pro Tech	0.00	N/A	N/A	N/A
INGN Inogen	2.50	Moderate Buy	$11.00	64.67% Upside
PROF Profound Medical	3.00	Buy	$11.00	92.98% Upside
TLSI TriSalus Life Sciences	3.25	Buy	$10.75	127.75% Upside

Current Analyst Ratings Breakdown

Latest APT, INGN, TLSI, and PROF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	INGN Inogen	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/15/2025	INGN Inogen	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
5/22/2025	INGN Inogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Moderate Buy	$12.00
5/9/2025	PROF Profound Medical	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Moderate Buy
5/8/2025	INGN Inogen	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$10.00 ➝ $7.00
4/23/2025	PROF Profound Medical	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $11.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APT Alpha Pro Tech	$58.18M	0.90	$0.38 per share	12.80	$5.29 per share	0.91
INGN Inogen	$335.70M	0.54	N/A	N/A	$7.30 per share	0.92
PROF Profound Medical	$10.68M	16.04	N/A	N/A	$2.01 per share	2.84
TLSI TriSalus Life Sciences	$32.14M	5.56	N/A	N/A	($0.83) per share	-5.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APT Alpha Pro Tech	$4.19M	$0.37	12.97	∞	N/A	6.99%	6.70%	5.76%	N/A
INGN Inogen	-$35.89M	-$1.15	N/A	N/A	N/A	-8.08%	-14.76%	-9.01%	8/5/2025 (Estimated)
PROF Profound Medical	-$27.82M	-$1.22	N/A	N/A	N/A	-269.35%	-70.41%	-57.22%	8/6/2025 (Estimated)
TLSI TriSalus Life Sciences	-$30.05M	-$1.12	N/A	N/A	N/A	-84.67%	N/A	-111.63%	8/13/2025 (Estimated)

Latest APT, INGN, TLSI, and PROF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PROF Profound Medical	-$0.43	N/A	N/A	N/A	$4.75 million	N/A
8/13/2025	Q2 2025	TLSI TriSalus Life Sciences	-$0.22	N/A	N/A	N/A	$10.69 million	N/A
8/5/2025	Q2 2025	INGN Inogen	-$0.25	N/A	N/A	N/A	$90.40 million	N/A
5/15/2025	Q1 2025	TLSI TriSalus Life Sciences	-$0.20	-$0.33	-$0.13	-$0.39	$9.04 million	$9.17 million
5/8/2025	Q1 2025	PROF Profound Medical	-$0.29	-$0.36	-$0.07	-$0.36	$4.78 million	$2.62 million
5/7/2025	Q1 2025	INGN Inogen	-$0.52	-$0.25	+$0.27	-$0.25	$79.57 million	$82.28 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APT Alpha Pro Tech	N/A	N/A	N/A	N/A	N/A
INGN Inogen	N/A	N/A	N/A	N/A	N/A
PROF Profound Medical	N/A	N/A	N/A	N/A	N/A
TLSI TriSalus Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APT Alpha Pro Tech	N/A	19.00	11.21
INGN Inogen	N/A	3.07	2.67
PROF Profound Medical	0.09	11.31	10.03
TLSI TriSalus Life Sciences	N/A	2.14	1.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APT Alpha Pro Tech	22.69%
INGN Inogen	89.94%
PROF Profound Medical	47.86%
TLSI TriSalus Life Sciences	2.58%

Insider Ownership

Company	Insider Ownership
APT Alpha Pro Tech	15.00%
INGN Inogen	1.46%
PROF Profound Medical	1.52%
TLSI TriSalus Life Sciences	27.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APT Alpha Pro Tech	120	10.86 million	9.46 million	Optionable
INGN Inogen	1,030	26.89 million	26.49 million	Optionable
PROF Profound Medical	150	30.05 million	29.60 million	Optionable
TLSI TriSalus Life Sciences	106	37.84 million	27.43 million	Not Optionable

APT, INGN, TLSI, and PROF Headlines

Recent News About These Companies

TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Business Wire

June 25, 2025 | businesswire.com

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

June 23, 2025 | businesswire.com

TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience

May 30, 2025 | businesswire.com

Jodi Devlin Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock

May 22, 2025 | insidertrades.com

TriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable market

May 15, 2025 | msn.com

TriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates

May 15, 2025 | zacks.com

TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

May 15, 2025 | businesswire.com

TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

May 12, 2025 | businesswire.com

TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

April 30, 2025 | finance.yahoo.com

TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?

April 9, 2025 | zacks.com

TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?

April 9, 2025 | zacks.com

TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks

March 30, 2025 | seekingalpha.com

Trisalus outlines 50% revenue growth target for 2025 driven by TriNav expansion and new market penetration

March 27, 2025 | msn.com

TriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays Pessimistic

March 27, 2025 | msn.com

TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript

March 27, 2025 | seekingalpha.com

TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates

March 27, 2025 | zacks.com

TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

March 27, 2025 | businesswire.com

3 Stocks With Robust Growth Outlooks Insiders Are Buying (TLSI)

February 19, 2025 | insidertrades.com

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Purchases $33,900.00 in Stock

February 7, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Marvell's New AI Chip Deals Capture Wall Street’s Attention
By Jeffrey Neal Johnson | June 21, 2025
View Marvell's New AI Chip Deals Capture Wall Street’s Attention
Nebius Group: Up 385%, Analysts Say It’s Still a Bargain
By Jeffrey Neal Johnson | July 10, 2025
View Nebius Group: Up 385%, Analysts Say It’s Still a Bargain
Enovix Shares Hit 6-Month High; Long-Term Highs to Follow
By Thomas Hughes | July 10, 2025
View Enovix Shares Hit 6-Month High; Long-Term Highs to Follow
Why Freeport-McMoRan Is The Copper King in a Tight Market
By Jeffrey Neal Johnson | July 7, 2025
View Why Freeport-McMoRan Is The Copper King in a Tight Market
Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer
By Jeffrey Neal Johnson | June 19, 2025
View Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer

APT, INGN, TLSI, and PROF Company Descriptions

Alpha Pro Tech NYSE:APT

$4.80 +0.10 (+2.13%)

Closing price 04:00 PM Eastern

Extended Trading

$4.76 -0.04 (-0.73%)

As of 04:04 PM Eastern

Alpha Pro Tech, Ltd., together with its subsidiaries, develops, manufactures, and markets a range of disposable protective apparel, infection control, and building supply products in the United States and internationally. The company operates through Disposable Protective Apparel and Building Supply segments. The Disposable Protective Apparel segment provides shoe covers, bouffant caps, coveralls, frocks, lab coats, and gowns, hoods, as well as face masks and shields. The Building Supply segment offers construction weatherization products, such as housewrap and housewrap accessories, including window and door flashing, and seam tape, synthetic roof underlayment, and self-adhered roof underlayment, as well as other woven material. The company markets its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada.

Inogen NASDAQ:INGN

$6.68 +0.14 (+2.14%)

Closing price 04:00 PM Eastern

Extended Trading

$6.77 +0.09 (+1.41%)

As of 06:53 PM Eastern

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

Profound Medical NASDAQ:PROF

$5.70 -0.06 (-1.04%)

Closing price 03:59 PM Eastern

Extended Trading

$5.66 -0.04 (-0.79%)

As of 04:04 PM Eastern

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

TriSalus Life Sciences NASDAQ:TLSI

$4.72 +0.01 (+0.21%)

Closing price 04:00 PM Eastern

Extended Trading

$4.74 +0.02 (+0.42%)

As of 04:04 PM Eastern

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time